This biweekly newsletter provides concise, independent coverage and analysis of fast-breaking lab, pathology, blood banking, imaging and diagnostic radiology news from the Nation's Capital. You'll find out about: Medicare payment and policy directives Billing guidelines and coding changes for diagnostic facilities CLIA & MQSA regulatory mandates, changes and interpretations Congressional actions & legislative initiatives Federal compliance requirements OIG anti-fraud initiatives, Stark self-referral prohibitions, plus other legal news FDA oversight of in vitro diagnostics, blood banks, and radiological devices OSHA, NRC, and state safety standards.
Clinical laboratories will face major operational problems if the Centers for Medicare and Medicaid Services (CMS) reverses longstanding Medicare policy and goes ahead with its proposal to require the signature of a physician or a nonphysician practitioner (NPP) on all requisitions for tests paid via the Part B lab fee schedule.
Leading scientific societies and national clinical laboratory and pathology groups are among those who responded to the call for comment on how to set payment rates for CPT and HCPCS codes to be added to the Part B lab fee schedule, as of Jan. 1, 2011.
For renal dialysis facilities and clinical laboratories that serve them, major changes are in store next year under a final rule implementing Medicares transition to a new prospective payment system for outpatient dialysis services to beneficiaries with end-stage renal disease (ESRD). The changeover is required by the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA).
For more than 11 years, the American Association of Bioanalysts (AAB) has fought a court battle against the New York State Department of Health, claiming that it was intentionally overcharging clinical laboratories so that it could subsidize its many other research programs that had no relation to covering the necessary costs of regulating clinical labs and blood banks.
National Intelligence Report is part of...